Frontera Therapeutics Doses First Patient In Phase 1 Clinical Trial For Gene Therapy Ft-001 For The Treatment Of Leber Congenital Amaurosis-2
A Global Clinical-Stage Biotechnology Company That Seeks To Develop Novel And Best-In-Class Gene Therapy Medicines To Improve The Lives Of Patients Across Multiple Disease Areas, Today Announced That It Has Dosed The First Patient In A Phase 1 Clinical Trial Of Its Lead Gene Therapy Program, Ft-001, For The Treatment Of Leber Congenital Amaurosis-2, A Severe Inherited Retinal Disease Related To A Mutation In The Rpe65 Gene. Ft-001 Is Administered By A One-Time Injection Into The Subretinal Space Of The Eye That Delivers A Functional Copy Of The Human Rpe65 Gene To The Nuclei Of The Patient
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
